Century Therapeutics Announces Appointment of Michael C. Diem as Chief Business Officer

Sept. 16, 2020 11:00 UTC



PHILADELPHIA--(BUSINESS WIRE)-- Century Therapeutics, Inc., developer of induced pluripotent stem cell (iPSC)-derived allogeneic cell therapies for cancer, today announced the appointment of Michael C. Diem, MD, as Chief Business Officer. Dr. Diem has more than 15 years of experience in the global pharmaceutical and biotech industries and nearly 10 years of experience in academic and clinical medicine.

“I am excited to welcome Mike to Century as he shares our commitment to building the company and developing its innovative science. Mike’s extensive leadership experience in corporate strategy and business development at top global life sciences companies is a win for Century as we expand our business operations to fully realize our platform’s potential to help cancer patients,” said Lalo Flores, PhD, Chief Executive Officer of Century Therapeutics.

Most recently, Dr. Diem served as Senior Vice President and Head of Corporate and Business Development at Amicus Therapeutics, where he developed and executed the company’s long-term transformational strategies building its diversified portfolio. He also held similar roles at other leading pharmaceutical companies including AstraZeneca and GlaxoSmithKline. Additionally, he brings experience from serving as a board member at numerous life science and biotechnology companies.

“I look forward to joining the Century Therapeutics team, helping to craft the company’s business strategy to support our ultimate goal of developing curative cell therapy products for cancer patients,” said Dr. Diem. “Century’s allogeneic cell therapy products show immense potential to overcome the limitations of first-generation cell therapies, and I am excited to work with this world-class team to bring innovative therapies to the patients who need them most.”

Dr. Diem received his Doctor of Medicine from the Rutgers-Robert Wood Johnson Medical School, completed his medical training at Duke University Medical Center and is an alumnus of the Kauffman Fellows Program. He holds a Master of Business Administration from the Weatherhead School of Management at Case Western Reserve University and a BA in biological sciences from Rutgers University.

About Century Therapeutics
Century Therapeutics is harnessing the power of stem cells to develop curative cell therapy products for cancer that overcome the limitations of first-generation cell therapies. Our genetically engineered, universal iPSC-derived immune effector cell products (iNK, iT) are designed to specifically target hematologic and solid tumor cancers. Our commitment to developing off-the-shelf cell therapies will expand patient access and provides an unparalleled opportunity to advance the course of cancer care. Century was launched in 2019 by founding investor Versant Ventures in partnership with Fujifilm and Leaps by Bayer. For more information, please visit www.centurytx.com.


Betsy Yates


Source: Century Therapeutics

Back to news